New imaging tracer could spot aggressive breast cancer spread
NCT ID NCT06962163
First seen Jan 12, 2026 · Last updated Jun 22, 2026 · Updated 19 times
Summary
This pilot study tests a new PET/CT scan using a tracer called [68Ga]Ga-PentixaFor in 12 people with metastatic triple-negative breast cancer. The goal is to see if this scan can detect cancer spread as well as the standard FDG PET/CT, and whether it can identify tumors that might respond to future targeted treatments. Participants will receive the new scan at the start of the study and again if their disease progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut de cancerologie de l'Ouest
RECRUITINGSaint-Herblain, 44805, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-PentixaFor (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this imaging method could help identify patients whose tumors express CXCR4, potentially guiding them to more effective targeted therapies.
What could go wrong
This is a very early pilot study with only 12 participants, so results may not apply broadly. The tracer's ability to improve outcomes over standard imaging is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.